Preventing Recurrent Clostridioides difficile Infections with Fecal Microbiota-Based Therapies : Episode 1

Epidemiology of C. difficile Infections in the US

August 26, 2024

By Paul Feuerstadt, MD
Carl V. Crawford, MD

Opinion

Video

A panel of experts provide an overview of the epidemiology of Clostridioides difficile infections, highlighting diagnostic practices and the role of antimicrobial stewardship.

Now Viewing

EP: 1.Epidemiology of C. difficile Infections in the US

EP: 2.Recurrence of C. Difficile Infections

EP: 3.Risk Factors for C. difficile Infections

EP: 4.Patients at Risk for Recurrent C. difficile Infections and the Role of Environmental Factors

EP: 5.Diagnostic Tests for C. difficile Infections

EP: 6.Treatment Guidelines for C. difficile Infection

EP: 7.Factors Contributing to C. difficile Infection Recurrence

EP: 8.Managing C. difficile Infections in the Clinic

EP: 9.Contribution of Unnecessary and Prolonged Antibiotic Use to Recurrent C. difficile Infections

EP: 10.Fecal Microbiota Transplantation for C. difficile Infections

EP: 11.Recent Fecal Microbiota Transplant Approvals for C. difficile Infections

EP: 12.Administration of FDA-Approved Fecal Microbiota Transplants for C. difficile Infections in Clinical Practice

EP: 13.Data on Fecal Microbiota, Live-JSLM (RBL) for C. difficile Infections

EP: 14.ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections

EP: 15.Safety of Fecal Microbiota Options and Transfer of Food-Borne Allergens

EP: 16.Utilization of Fecal Microbiota Transplant Products in Clinical Practice

EP: 17.Physicians’ Use of Fecal Microbiota Transplant for Recurrent C. difficile Infections

EP: 18.Tips for Talking with Patients about Fecal Microbiota Transplant for Recurrent C. difficile Infections

Video content above is prompted by the following:

How often do we see C. difficile infections (CDI) in the general population in the US?